Knight Therapeutics Inc. (TSE:GUD – Free Report) – Raymond James Financial lifted their FY2025 earnings estimates for Knight Therapeutics in a research report issued to clients and investors on Wednesday, June 18th. Raymond James Financial analyst M. Freeman now expects that the company will earn $0.15 per share for the year, up from their previous forecast of $0.14. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Raymond James Financial also issued estimates for Knight Therapeutics’ Q1 2026 earnings at $0.01 EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at $0.07 EPS.
A number of other research firms have also issued reports on GUD. Stifel Nicolaus boosted their price objective on Knight Therapeutics from C$6.25 to C$7.45 and gave the company a “buy” rating in a research report on Tuesday, March 25th. Research Capitl upgraded Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 11th. Finally, Canaccord Genuity Group set a C$6.50 price target on shares of Knight Therapeutics and gave the stock a “buy” rating in a research report on Friday, May 9th. Two research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Strong Buy” and a consensus price target of C$7.15.
Knight Therapeutics Stock Up 0.2%
TSE:GUD opened at C$5.85 on Thursday. The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52. The stock has a 50 day moving average of C$5.87 and a 200-day moving average of C$5.70. The firm has a market capitalization of C$591.73 million, a PE ratio of -19.53, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. Knight Therapeutics has a 52 week low of C$5.09 and a 52 week high of C$6.45.
About Knight Therapeutics
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Featured Articles
- Five stocks we like better than Knight Therapeutics
- What is a Stock Market Index and How Do You Use Them?
- New All-Time Highs Coming for Broadcom? Wall Street Says Yes
- What is Short Interest? How to Use It
- Overheated Market? Analysts Watch These Red Flags
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- 3 Reasons AMD Could Be the Hottest Stock of the Summer
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.